Mozobil for Autologous Hematopoietic Stem Cell Transplantation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Multiple MyelomaHodgkin LymphomaNon-hodgkin Lymphoma
Interventions
DRUG

Plerixafor

Plerixafor is an antagonist of chemokine receptor-4 (CXCR4) receptor that can release stem cells from the bone marrow niche into the peripheral blood circulation

DRUG

Gcsf

All patients will receive G-CSF (peg-filgrastim or filgrastim) starting on day -4, prior to planned peripheral blood stem cell collection on day 0.

All Listed Sponsors
lead

Thomas Jefferson University

OTHER

NCT07188090 - Mozobil for Autologous Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter